Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study

• DOI: 10.1176/appi.ajp.2007.07010079
• Publication Date: 2008-02-02T01:44:40Z
• Authors: Ren-Rong Wu; Jing-Ping Zhao; Xiao-Feng Guo; Yi-Qun He; Mao-Sheng Fang; Wen-Bin Guo; Jin-Dong Chen; Le-Hua Li
• Keywords: Dopamine antagonist

Objective: The purpose of this study was to assess the efficacy metformin in preventing olanzapine-induced weight gain. Method: Forty patients with schizophrenia were randomly assigned treatment for 12 weeks olanzapine, 15 mg/day, plus metformin, 750 mg/day (N=20), or placebo (N=20). This investigation conducted a double-blind fashion. Planned assessments included body weight, mass index, proportion who gained more than 7% their baseline at end 12-week treatment, waist circumference, waist-to-hip ratio, fasting glucose and insulin, insulin resistance scores on Scale Assessment Positive Symptoms (SAPS) Negative (SANS). Results: Of 40 assigned, 37 (92.5%) completed treatments. ratio levels increased less olanzapine group relative during follow-up period. index values significantly 8 12. In contrast, remained unchanged. Significantly fewer by 7%, which cutoff clinically meaningful There significant decrease SAPS SANS within each from week 12, no between-group differences. Metformin tolerated well all patients. Conclusions: effective safe attenuating gain drug-naive first-episode Patients displayed good adherence type preventive intervention.